CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
13.48
+0.37 (2.82%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery.

The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

CervoMed Inc.
CervoMed logo
Country United States
Founded 2001
Industry Biotechnology
Sector Healthcare
Employees 8
CEO John Alam

Contact Details

Address:
20 Park Plaza, Suite 424
Boston, Massachusetts 02116
United States
Phone 617 744 4400
Website cervomed.com

Stock Details

Ticker Symbol CRVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001053691
ISIN Number US15713L1098
Employer ID 30-0645032
SIC Code 2834

Key Executives

Name Position
Dr. John J. Alam M.D. Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D. Co-Founder and Director
William Robert Elder J.D. Chief Financial Officer and General Counsel
Dr. Robert J. Cobuzzi Jr., Ph.D. Chief Operating Officer and Director
Kelly Blackburn M.H.A. Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Oct 16, 2024 8-K Current Report
Oct 11, 2024 424B3 Prospectus
Oct 10, 2024 EFFECT Notice of Effectiveness
Oct 10, 2024 424B3 Prospectus
Oct 9, 2024 EFFECT Notice of Effectiveness
Oct 3, 2024 S-3 Registration statement under Securities Act of 1933
Oct 3, 2024 POS AM Post-Effective amendments for registration statement
Oct 3, 2024 8-K Current Report
Oct 1, 2024 424B3 Prospectus
Oct 1, 2024 8-K Current Report